Cognition Therapeutics
$1.0200
103
+$0.00+0% 10:26 Today
Statistics
Day High
1.025
Day Low
1.015
52W High
3.83
52W Low
0.55
Volume
2,038
Avg. Volume
-
Mkt Cap
97M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.19
-0.14
-0.09
-0.04
Expected EPS
-0.066667
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-23.49MNet Income
Analyst Ratings
4.00Average Price Target
The highest estimate is 4.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CGTX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31B
Lilly(Eli) &
LLY
Mkt Cap1.05T
Acadia Pharmaceuticals
ACAD
Mkt Cap4.87B
Anavex Life Sciences
AVXL
Mkt Cap298.48M
Axsome Therapeutics
AXSM
Mkt Cap11.19B
Prothena
PRTA
Mkt Cap454.85M
AnaptysBio
ANAB
Mkt Cap1.73B
About
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Show more...
CEO
Lisa Ricciardi
Employees
14
Country
United States
ISIN
US19243B1026
Listings
0 Comments
Share your thoughts
FAQ
What is Cognition Therapeutics stock price today?▼
The current price of CGTX is $1.02 USD — it has increased by +0% in the past 24 hours. Watch Cognition Therapeutics stock price performance more closely on the chart.
What is Cognition Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cognition Therapeutics stocks are traded under the ticker CGTX.
Is Cognition Therapeutics stock price growing?▼
CGTX stock has risen by +0% compared to the previous week, the month change is a +6.16% rise, over the last year Cognition Therapeutics has showed a -31.54% decrease.
What is Cognition Therapeutics market cap?▼
Today Cognition Therapeutics has the market capitalization of 97M
When is the next Cognition Therapeutics earnings date?▼
Cognition Therapeutics is going to release the next earnings report on November 18, 2026.
What were Cognition Therapeutics earnings last quarter?▼
CGTX earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.06 USD resulting in a +36.84% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cognition Therapeutics revenue for the last year?▼
Cognition Therapeutics revenue for the last year amounts to 0 USD.
What is Cognition Therapeutics net income for the last year?▼
CGTX net income for the last year is -23.49M USD.
How many employees does Cognition Therapeutics have?▼
As of August 18, 2026, the company has 14 employees.
In which sector is Cognition Therapeutics located?▼
Cognition Therapeutics operates in the Health & Wellness sector.
When did Cognition Therapeutics complete a stock split?▼
Cognition Therapeutics has not had any recent stock splits.
Where is Cognition Therapeutics headquartered?▼
Cognition Therapeutics is headquartered in PURCHASE, United States.